Fredag 13 Juni | 06:42:18 Europe / Stockholm

Prenumeration

2025-06-10 08:58:00

Curasight is advancing its mission to transform cancer care through its uPAR-based theranostics platform. Following a rights issue that raised DKK 47 million, the company is now accelerating the development of its diagnostic and therapeutic solutions. We spoke with CEO Ulrich Krasilnikoff to hear what lies ahead.

Read the full interview withat biostock.se:

https://biostock.se/en/2025/06/curasights-ceo-we-will-deliver-key-milestones-in-the-next-12-months/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/